Risk stratification in cardiovascular disease primary prevention - scoring systems, novel markers, and imaging techniques.

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F12%3A%230000464" target="_blank" >RIV/00064190:_____/12:#0000464 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1111/j.1472-8206.2011.01023.x" target="_blank" >http://dx.doi.org/10.1111/j.1472-8206.2011.01023.x</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/j.1472-8206.2011.01023.x" target="_blank" >10.1111/j.1472-8206.2011.01023.x</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Risk stratification in cardiovascular disease primary prevention - scoring systems, novel markers, and imaging techniques.

Popis výsledku v původním jazyce

The aim of this paper is to review and discuss current methods of risk stratification for cardiovascular disease (CVD) prevention, emerging biomarkers, and imaging techniques, and their relative merits and limitations. This report is based on discussionsthat took place among experts in the area during a special CardioVascular Clinical Trialists workshop organized by the European Society of Cardiology Working Group on Cardiovascular Pharmacology and Drug Therapy in September 2009. Classical risk factorssuch as blood pressure and low-density lipoprotein cholesterol levels remain the cornerstone of risk estimation in primary prevention but their use as a guide to management is limited by several factors: (i) thresholds for drug treatment vary with the available evidence for cost-effectiveness and benefit-to-risk ratios; (ii) assessment may be imprecise; (iii) residual risk may remain, even with effective control of dyslipidemia and hypertension. Novel measures include C-reactive protein

Název v anglickém jazyce

Risk stratification in cardiovascular disease primary prevention - scoring systems, novel markers, and imaging techniques.

Popis výsledku anglicky

The aim of this paper is to review and discuss current methods of risk stratification for cardiovascular disease (CVD) prevention, emerging biomarkers, and imaging techniques, and their relative merits and limitations. This report is based on discussionsthat took place among experts in the area during a special CardioVascular Clinical Trialists workshop organized by the European Society of Cardiology Working Group on Cardiovascular Pharmacology and Drug Therapy in September 2009. Classical risk factorssuch as blood pressure and low-density lipoprotein cholesterol levels remain the cornerstone of risk estimation in primary prevention but their use as a guide to management is limited by several factors: (i) thresholds for drug treatment vary with the available evidence for cost-effectiveness and benefit-to-risk ratios; (ii) assessment may be imprecise; (iii) residual risk may remain, even with effective control of dyslipidemia and hypertension. Novel measures include C-reactive protein

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Fundamental & clinical pharmacology

ISSN

0767-3981

e-ISSN

—

Svazek periodika

26

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

12

Strana od-do

163-174

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—